Many women avoid menopause hormone therapy because of fears rooted in 2002 headlines. Long-term research shows risk depends on age, timing, and hormone type. In 2025, the FDA began removing broad boxed-warning language about cardiovascular disease, breast cancer, and dementia, though the endometrial cancer warning remains for systemic estrogen alone. “Bioidentical” isn’t a safety rating, and compounded hormones fit specific needs. Your clinician can help you weigh your personal risks.
You haven’t slept through the night in months. Hot flashes interrupt meetings, and intimacy has become painful.
Yet when a friend asks why you haven’t tried hormone therapy, the answer comes fast: “Isn’t it dangerous? Doesn’t it cause cancer?” Hormone therapy myths like these keep many women from even starting the conversation with their doctor.
Those fears didn’t come from nowhere. They trace back to a major study and the alarming headlines that followed it more than two decades ago. But science has moved on. Long-term follow-up has added important context, and the Menopause Society now says that for many healthy women with symptoms, the benefits generally outweigh the risks.
Regulators have moved, too. In late 2025, the FDA began changing the warnings on menopausal hormone therapy labels.
In this article, our pharmacists separate common myths from what the evidence actually shows, including an honest look at compounded hormones. Our goal is to help you walk into your next appointment better informed. You can also learn more about our women’s health and hormone compounding services.
Where Hormone Therapy Myths Started: The WHI Study
Most hormone therapy myths trace back to July 2002, when the Women’s Health Initiative (WHI) stopped its estrogen-plus-progestin trial early after finding higher risks of breast cancer and cardiovascular events. Later analyses showed participants averaged 63 years old, and that age and timing significantly change the risk-benefit picture.
What the 2002 trial found
The WHI estrogen-plus-progestin trial enrolled more than 16,600 women and was halted on July 9, 2002. Researchers saw more invasive breast cancer, heart disease, strokes, and blood clots in the lungs among women taking hormones. The news spread quickly, and prescriptions dropped sharply.
What got less attention was who was in the study. As HHS noted in its 2025 announcement, participants averaged 63, more than a decade past the typical start of menopause.
What long-term follow-up showed
Researchers continued to track WHI participants for about 18 years. An analysis of 27,347 women, reported by TCTMD, found hormone therapy did not raise overall death rates. Women who started in their 50s had a lower death rate than those on placebo.
That doesn’t erase the original findings. It does show why a single headline turned into one of the most lasting hormone therapy myths: the idea that the risks are the same for every woman, at every age.
“The women in the study behind two decades of fear averaged 63, well past typical menopause.”
Myth: Hormone Therapy Always Causes Breast Cancer
Not exactly. In long-term WHI follow-up, estrogen plus progestin was linked to more breast cancer diagnoses, while estrogen alone in women who had a hysterectomy was linked to fewer cases and fewer breast cancer deaths. Risk depends on hormone type, duration, personal history, and timing.
Estrogen plus progestin vs. estrogen alone
Progestin is a hormone given with estrogen to protect the uterus lining. Healio reported on WHI long-term data showing about a 29% higher breast cancer incidence with the combination. Estrogen alone, used only by women without a uterus, was tied to about 23% lower incidence and fewer breast cancer deaths.
Your history still matters
None of these findings means hormone therapy is “safe” for everyone. A personal or family history of breast cancer, blood clots, stroke, or liver disease can affect your risk. That is why this decision belongs with your clinician.
It also helps to ask about the type of hormone, the route, and how long you might use it. Those details shape risk far more than the general label “hormone therapy.” A good clinician will walk through your numbers, not someone else’s headline.
What Changed: FDA’s Hormone Therapy Boxed Warning Update
In November 2025, the FDA began removing boxed-warning language about cardiovascular disease, breast cancer, and probable dementia from menopausal hormone therapy labels. In February 2026 it approved the first six revised labels. The endometrial cancer boxed warning still appears on systemic estrogen-alone products, and the label still describes the risks elsewhere.
What was removed and what stayed
A boxed warning (often called a “black box”) is the FDA’s most prominent label caution. According to HHS, the agency asked manufacturers to drop the broad boxed language on heart disease, breast cancer, and dementia. It kept the boxed warning about endometrial cancer, which is cancer of the uterine lining, for systemic estrogen used without a progestogen.
The FDA approved the first revised labels on February 12, 2026, for six products. Twenty-nine companies submitted changes, so updates are rolling out label by label.
The timing window
The updated labels are meant to recommend starting systemic hormone therapy before age 60 or within 10 years of menopause onset. “Systemic” means the hormone travels through the bloodstream, as with pills, patches, or gels.
What this doesn’t mean
The change does not make hormone therapy risk-free. Labels still describe known risks in their other sections, and the update applies only to FDA-approved products. Compounded hormones have no FDA-approved label at all.
Because the rollout happens one product at a time, the label on your specific medication may or may not reflect the new wording yet. Your pharmacist can show you the current label and explain what it says.
Myth: “It’s Too Late for Hormone Therapy After 60”
Age matters, but there is no universal cutoff. The Menopause Society’s 2022 position statement calls hormone therapy the most effective treatment for hot flashes and night sweats. It says benefits generally outweigh risks for healthy women under 60 or within 10 years of menopause.
No automatic stop date
The same statement says hormone therapy does not need to be routinely stopped at 60 or 65. Women with ongoing symptoms can consider continuing after a careful evaluation and counseling.
Starting later is a more individual decision. Your clinician will weigh your heart and clot risks, along with how much your symptoms affect daily life.
Why timing matters
Researchers call this phenomenon the “timing hypothesis.” The idea is that hormone therapy started near menopause behaves differently from therapy started many years later, when blood vessels may have already changed. The WHI follow-up, where women in their 50s fared better, fits that pattern.
Local options for vaginal symptoms
Vaginal dryness and painful intercourse often persist for years after menopause, and they tend to worsen rather than fade with time. Low-dose local therapy acts mainly where it is applied, so many women discuss it with their clinician even when systemic therapy isn’t a fit. Read more about options for vaginal dryness after menopause.
Myth: “Natural” and “Bioidentical” Are Always Safer
This myth runs in the opposite direction. Instead of scaring women away from treatment, it pushes some toward products marketed as gentler or more natural.
Bioidentical is a description, not a safety rating
“Bioidentical” means a hormone has the same molecular structure as the one your body makes. It describes chemistry, not safety. Cleveland Clinic explains that FDA-approved bioidentical estradiol and progesterone products exist, and they have been tested to meet FDA standards.
“Natural” can mislead
Plant-derived hormones, often made from yams or soy, are processed in a lab before they become medication. Your body can’t tell where the molecule started. What matters is the dose, the route, and how well the product is made.
Marketing claims have drawn FDA attention
Claims that compounded versions are safer or more effective remain unsupported. In 2008, the FDA sent warning letters to several pharmacy operations over that kind of marketing. At King’s, we don’t make those claims.
“Bioidentical describes a molecule and its structure, not a safety record or a guarantee.”
Compounded Hormone Therapy: The Honest Facts
Compounded hormones are not FDA-approved. Major groups, including the National Academies (NASEM), ACOG, and the Menopause Society, advise using FDA-approved products when they fit. NASEM said compounded hormones may be appropriate when a patient is allergic to an ingredient in an approved product or needs a dosage form not commercially available.
What NASEM recommended
In its 2020 FDA-sponsored report, the National Academies found insufficient evidence to support the clinical usefulness of compounded bioidentical hormones. It urged prescribers to limit them to specific medical needs and raised concerns about hormone pellets.
The report also recommended that the FDA review several hormones for its “difficult to compound” list. ACOG’s 2023 guidance agrees that compounded hormones shouldn’t be routine when an FDA-approved option works, and it does not recommend hormone level testing to guide dosing.
When compounding makes sense
ACOG gives a practical example: preparing progesterone without peanut oil for a woman with a peanut allergy. Other cases include a strength or form that isn’t commercially available. See our guide to perimenopause symptoms and when compounded hormones may help.
Choosing a quality pharmacy
If your prescriber orders a compounded hormone, choose a pharmacy that is NABP accredited, follows USP standards, and lets you speak with a pharmacist. King’s meets those marks as part of our personalized compounding services.
Getting Help: Questions to Bring to Your Clinician
Hormone therapy myths shouldn’t make your decision for you. Age, timing, hormone type, and your personal history all shape the answer, and the best choice is the one you make with a clinician who knows your history.
Bring these questions to your appointment: Am I within the timing window? Would systemic or local therapy fit my symptoms? Is there an FDA-approved option, or do I need something compounded?
Have questions about whether a compounded hormone is right for you? Talk to your prescribing physician, then connect with the pharmacists at King’s Pharmacy and Compounding Center in Irvine, CA. Contact King’s Pharmacy at 949.387.0780.
Frequently Asked Questions
Did the FDA remove the black box warning on hormone therapy?
Partly. In November 2025 the FDA began removing boxed-warning language about cardiovascular disease, breast cancer, and probable dementia, approving the first six revised labels in February 2026. The endometrial cancer boxed warning remains on systemic estrogen-alone products.
Does hormone therapy cause breast cancer?
It depends on the type. In long-term WHI follow-up, estrogen plus progestin was linked to more breast cancer diagnoses, while estrogen alone after hysterectomy was linked to fewer. Discuss your personal risk with your clinician.
Am I too old to start hormone therapy?
The Menopause Society says benefits generally outweigh risks for healthy women under 60 or within 10 years of menopause onset. Outside that window, the decision is more individual. Your clinician will consider your heart, clot, and cancer risks.
Are bioidentical hormones safer than FDA-approved hormones?
“Bioidentical” describes molecular structure, not safety, and FDA-approved bioidentical estradiol and progesterone products already exist. There is no strong evidence that compounded bioidentical hormones are safer or more effective than FDA-approved options.
When is a compounded hormone appropriate?
The National Academies and ACOG point to specific situations, such as an allergy to an ingredient in an FDA-approved product or a need for a dosage form that isn’t commercially available. Compounded hormones are not FDA-approved and require a prescription.
This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Compounded medications require a valid prescription from a licensed prescriber. Always speak with your physician about your specific health needs.
